Halozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year High – Time to Buy?

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) reached a new 52-week high on Thursday . The stock traded as high as $84.49 and last traded at $83.8980, with a volume of 28401 shares changing hands. The stock had previously closed at $83.59.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HALO shares. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. UBS Group restated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Stock Down 0.3%

The firm has a market capitalization of $9.89 billion, a price-to-earnings ratio of 29.95, a P/E/G ratio of 0.34 and a beta of 0.85. The firm has a fifty day moving average price of $75.39 and a 200 day moving average price of $71.15. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business’s revenue was up 42.2% on a year-over-year basis. During the same period last year, the firm posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the transaction, the director directly owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 72,477 shares of company stock valued at $5,102,643 over the last ninety days. 2.50% of the stock is owned by insiders.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC lifted its holdings in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC increased its stake in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the period. Harbour Investments Inc. raised its position in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 372 shares during the last quarter. Clearstead Advisors LLC raised its position in shares of Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 331 shares during the last quarter. Finally, Wexford Capital LP acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at $70,000. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.